本研究调查了口服补充胃蛋白酶可溶性鸡Ⅱ型胶原（PSCC-II）是否减轻了大鼠前交叉韧带断裂（ACLT）引起的骨关节炎（OA）的进展。随机将8周龄雄性Wistar大鼠分为以下组别：对照组、假手术组、ACLT组、A组（ACLT + 胃酶可溶性Ⅱ型胶原（C-II）与Ⅰ型胶原）、B组（ACLT + Amano M可溶性C-II与Ⅰ型胶原）、C组（ACLT + 高剂量Amano M可溶性C-II与Ⅰ型胶原）和D组（ACLT + 未被蛋白酶降解的C-II）。采用多种方法对膝关节进行分析：伤害感应测试、微计算机断层扫描、组织病理学和免疫组织化学。任何形式的C-II处理的大鼠均显著降低了疼痛敏感性和软骨降解。接受PSCC-II治疗的组别在模型组ACLT造成的骨关节炎方面，包括松质骨体积、小梁数量和小梁间隔均得到了有效缓解。此外，PSCC-II和未被蛋白酶降解的C-II抑制了ACLT诱导的C-II下调和基质金属蛋白酶-13、肿瘤坏死因子-α和白细胞介素-1β上调等效应。这些结果表明，PSCC-II治疗保留了传统未变性C-II的保护效果，并为OA治疗提供了更优越的益处。这些益处包括缓解疼痛、抗炎作用以及对软骨和松质骨的保护。

This study investigated whether oral supplementation with protease-soluble chicken type II collagen (PSCC-II) mitigates the progression of anterior cruciate ligament transection (ACLT)-induced osteoarthritis (OA) in rats. Eight-week-old male Wistar rats were randomly assigned to the following groups: control, sham, ACLT, group A (ACLT + pepsin-soluble collagen type II collagen (C-II) with type I collagen), group B (ACLT + Amano M-soluble C-II with type I collagen), group C (ACLT + high-dose Amano M-soluble C-II with type I collagen), and group D (ACLT + unproteolyzed C-II). Various methods were employed to analyze the knee joint: nociceptive tests, microcomputed tomography, histopathology, and immunohistochemistry. Rats treated with any form of C-II had significant reductions in pain sensitivity and cartilage degradation. Groups that received PSCC-II treatment effectively mitigated the ACLT-induced effects of OA concerning cancellous bone volume, trabecular number, and trabecular separation compared with the ACLT alone group. Furthermore, PSCC-II and unproteolyzed C-II suppressed ACLT-induced effects, such as the downregulation of C-II and upregulation of matrix metalloproteinase-13, tumor necrosis factor-α, and interleukin-1β. These results indicate that PSCC-II treatment retains the protective effects of traditional undenatured C-II and provide superior benefits for OA management. These benefits encompass pain relief, anti-inflammatory effects, and the protection of cartilage and cancellous bone.